一、董事会会议召开情况 证券代码：300199 证券简称：翰宇药业 公告编号：2025-013 深圳翰宇药业股份有限公司 第六届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于 2025 年 4 月 15 日以电子邮件并电话通知方式向公司全体董事发出了关于召开第六届董事会 第三次会议的通知。 本次会议于 2025 年 4 月 24 日下午 15:30 在公司龙华总部 2006 董事会会议 室以现场结合通讯方式召开。会议应出席董事 9 人，实际出席会议董事 9 人，其 中独立董事胡文言先生以通讯表决方式出席会议。本次会议由董事长曾少贵先生 召集和主持，公司监事及高级管理人员列席了本次会议。 本次会议的召集、召开符合《中华人民共和国公司法》和《公司章程》的有 关规定，会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过《关于公司<2024年年度报告>及其摘要的议案》； 经审核，董事会认为：编制和审核深圳翰宇药业股份有限公司 2024 年年度 报告及其摘要的程序符合法律、行 ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-016 一、2024年度公司基本情况 经立信会计师事务所（特殊普通合伙）审计，公司2024年度实现的合并报 表归属于上市公司股东的净利润为-173,654,017.08元，截至2024年12月31日，公 司合并报表可供股东分配利润为-1,850,366,010.01元，资本公积为1,447,838,319.10 元 ； 母 公 司 报 表 可 供 分 配 的 净 利 润 为 -1697962508.58 元 ， 资 本 公 积 为 1,457,804,617.34元。 二、2024年度利润分配预案说明 公司2024年度分红方案不触及其他风险警示情形： | 项目 | 2024 年度 | 2023 年度 | 2022 年度 | | --- | --- | --- | --- | | 现金分红总额（元） | 0.00 | 0.00 | 0.00 | | 回购注销总额（元） | 0.00 | 318,662,650.99 | 0.00 | | 归属于上市公司股东的净利润（元） | -173,654,017.08 | -513,876,149.69 | - ...

证券代码：300199 证券简称：翰宇药业 公告编号：2025-018 深圳翰宇药业股份有限公司 关于作废2022年限制性股票激励计划已授予尚未归属的 限制性股票的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳翰宇药业股份有限公司（以下简称"公司"或"翰宇药业"）于 2025 年 4 月 24 日召开第六届董事会第三次会议和第六届监事会第二次会议，审议通过 了《关于作废 2022 年限制性股票激励计划已授予尚未归属的限制性股票的议案》， 根据公司 2022 年限制性股票激励计划（以下简称"本次激励计划"）的规定及 公司 2022 年第一次临时股东大会的授权，公司董事会同意作废本次激励计划已 授予尚未归属的 758.50万股限制性股票。现将相关事项说明如下： 一、本激励计划已履行的相关审批程序 1、2022 年 3 月 24 日，公司召开第五届董事会第五次会议，审议通过了《关 于<公司 2022 年限制性股票激励计划（草案）>及其摘要的议案》《关于<公司 2022 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东大会授权董事 会办理 20 ...

深圳翰宇药业股份有限公司 审计报告及财务报表 二〇二四年度 信会师报字[2025]第 ZI10348 号 深圳翰宇药业股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-7 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-113 | 三、 事务所及注册会计师执业资质证明 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公允反映了翰宇药业 2024 年 12 月 31 日的合并及母公司 财务状况以及 2024 年度的合并及母公司经营成果和现金流量。 二、 形成审计意见的基础 我们按照中国注册会计师审计准则的规定执行了审计工作。审计 报告的"注册会计师对财务报表审计的责任"部分进一步阐述 ...

关于深圳翰宇药业股份有限公司 二〇二四年度 营业收入扣除情况表的鉴证报告 信会师报字[2025]第ZI10351号 关于深圳翰宇药业股份有限公司2024年度 营业收入扣除情况表的鉴证报告 信会师报字[2025]第ZI10351号 深圳翰宇药业股份有限公司全体股东： 我们审计了深圳翰宇药业股份有限公司(以下简称"翰宇药业公 司")2024 年度的财务报表，包括 2024 年 12 月 31 日的合并及母公司 资产负债表、2024 年度合并及母公司利润表、合并及母公司现金流量 表、合并及母公司所有者权益变动表和相关财务报表附注，并于 2025 年 4 月 24 日出具了报告号为信会师报字[2025]第 ZI10348 号的无保 留意见审计报告。 在对上述财务报表执行审计的基础上，我们接受委托，对后附的 翰宇药业公司2024年度营业收入扣除情况表（以下简称"营业收入扣 除情况表"）执行了合理保证的鉴证业务。 一、 管理层的责任 翰宇药业公司管理层的责任是按照《深圳证券交易所创业板股票 上市规则》和《深圳证券交易所创业板上市公司自律监管指南第1号— —业务办理》的相关规定编制营业收入扣除情况表，确保营业收入扣 除情况 ...

深圳翰宇药业股份有限公司 二〇二四年度 内部控制审计报告 信会师报字[2025]第 ZI10349 号 内部控制审计报告 信会师报字[2025]第 ZI10349 号 深圳翰宇药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了深圳翰宇药业股份有限公司（以下简称"翰宇药 业"）2024 年 12 月 31 日的财务报告内部控制的有效性。 一、 企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是翰宇药业董事会的责任。 二、 注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、 内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 第 1 页 中国注册会计师： 中国·上海 2025 年 ...

国浩律师（深圳）事务所 关于 深圳翰宇药业股份有限公司 二〇二二年限制性股票激励计划 作废限制性股票相关事项 的 法律意见书 北京·上海·深圳·杭州·广州·昆明·天津·成都·宁波·福州·西安·南京·南宁·济南·重庆 Beijing·Shanghai·Shenzhen·Hangzhou·Guangzhou·Kunming·Tianjin·Chengdu ·Ningbo ·Fuzhou·Xi`an·Nanjing·Nanning·Jinan·Chongqing 苏州·长沙·太原·武汉·贵阳·乌鲁木齐·郑州·石家庄·合肥·海南·青岛·南昌·大连·银川·拉孜 Suzhou·Changsha·Taiyuan·Wuhan ·Guiyang·Wulumuqi·Zhengzhou·Shijiazhuang·Hefei·Hainan·Qingdao·Nanchang·Dalian·Yinchuan·Lhatse 香港·巴黎·马德里·硅谷·斯德哥尔摩·纽约·马来西亚·柬埔寨 Hongkong·Paris·Madrid·Silicon Valley·Stockholm·New York·Malaysia·Cambodia 深圳市深 ...

翰宇药业（300199）公告，2025年第一季度营业收入3.1亿元，同比增长106.29%。净利润6986.84万 元，同比增长595.45%。 ...

Revenue and Profitability - The company's revenue for Q1 2025 reached ¥309,969,965.34, representing a 106.29% increase compared to ¥150,256,744.79 in the same period last year[5] - Net profit attributable to shareholders was ¥69,868,367.53, a significant turnaround from a loss of ¥14,102,003.37, marking a 595.45% increase[5] - Basic and diluted earnings per share improved to ¥0.08, compared to a loss of ¥0.02 per share in the same period last year, reflecting a 500.00% increase[5] - The net profit for the current period was ¥69,439,025.34, a turnaround from a net loss of ¥14,350,051.02 in the previous period[22] - The profit attributable to the parent company's shareholders was ¥69,868,367.53, compared to a loss of ¥14,102,003.37 in the prior period[23] - The company reported a total comprehensive income of ¥69,339,641.98, recovering from a loss of ¥14,111,841.40 in the previous period[23] Cash Flow - The net cash flow from operating activities was ¥40,425,295.32, up 166.79% from ¥15,152,592.91 in the previous year[5] - Cash flow from operating activities showed a significant improvement, with cash received from sales reaching ¥190,318,882.35, compared to ¥130,536,094.26 in the previous period[25] - The net cash flow from operating activities was $40,425,295.32, an increase from $15,152,592.91 in the previous period, indicating a significant improvement in operational efficiency[26] - Total cash inflow from financing activities was $70,000,000.00, while cash outflow amounted to $120,077,959.58, resulting in a net cash flow of -$50,077,959.58, reflecting a decrease in financing activities[26] - The total cash inflow from investment activities was $3,746,209.90, while cash outflow was $34,282,205.58, leading to a net cash flow of -$30,535,995.68, indicating a substantial investment in assets[26] - The company received $9,311,755.88 in tax refunds, contributing positively to cash inflows from operating activities[26] Assets and Liabilities - The total assets at the end of Q1 2025 were ¥3,038,045,570.70, a slight increase of 0.99% from ¥3,008,225,640.09 at the end of the previous year[5] - Total current assets amount to ¥494,618,808.48, an increase from ¥463,048,006.84 at the beginning of the period[18] - Total liabilities decreased slightly to ¥2,371,659,416.70 from ¥2,411,179,128.07, reflecting a reduction of approximately 1.6%[22] - The company has a total of ¥82,878,785.91 in contract liabilities, down from ¥124,478,071.04, indicating a reduction of approximately 33%[18] Shareholder Information - Total number of common shareholders at the end of the reporting period is 57,273[14] - The largest shareholder, Zeng Shaogui, holds 11.16% of shares, amounting to 98,533,635 shares, with 95,732,245 shares pledged[14] - The company is actively involved in financing activities, with a notable shareholder, Tibet Rongrui Investment Co., holding 5,286,600 shares through margin trading[15] Operating Costs and Expenses - The company's operating costs increased by 115.64% to ¥128,088,503.11, mainly due to higher formulation costs[10] - Total operating costs amounted to ¥231,507,233.07, compared to ¥156,147,173.76 in the prior period, indicating an increase of about 48.2%[22] - Cash paid to employees increased to ¥58,222,746.22 from ¥35,535,450.97, reflecting a rise in labor costs[26] Research and Development - The company has ongoing research and development efforts, with development expenditures amounting to ¥142,685,817.52, up from ¥136,673,090.93[18] - Research and development expenses rose to ¥21,707,434.32 from ¥18,999,351.04, an increase of approximately 9.0%[22] Inventory and Accounts Receivable - The increase in accounts receivable was 73.91%, reaching ¥166,562,869.28, primarily due to increased revenue[9] - Accounts receivable increased significantly to ¥166,562,869.28 from ¥95,773,533.23, indicating a growth of approximately 74%[18] - Inventory decreased to ¥225,749,209.48 from ¥238,630,347.88, reflecting a decline of about 5.4%[18] Audit and Reliability - The company did not undergo an audit for the first quarter report, which may affect the reliability of the financial data presented[28]

Financial Performance - The net profit attributable to shareholders of the company significantly reduced losses year-on-year, primarily due to changes in revenue structure and an increase in overseas revenue proportion[7]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 25% year-over-year growth[21]. - The company's operating revenue for 2024 reached ¥590,199,011.64, representing a 36.82% increase compared to ¥431,384,112.87 in 2023[26]. - The net profit attributable to shareholders improved to -¥173,654,017.08 in 2024, a 66.21% reduction in losses from -¥513,876,149.69 in 2023[26]. - The net cash flow from operating activities surged to ¥164,705,660.55, a significant increase of 4,757.21% compared to -¥3,536,573.51 in 2023[26]. - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was -¥239,652,787.96 in 2024, a 59.44% improvement from -¥590,913,670.38 in 2023[26]. - The basic and diluted earnings per share improved to -¥0.20 in 2024, a 65.52% increase from -¥0.58 in 2023[26]. - The company's weighted average return on equity improved to -26.02% in 2024, up 24.62% from -50.64% in 2023[26]. Revenue Growth and Market Expansion - The overseas sales of peptide formulations and active pharmaceutical ingredients continued to grow, driving overall revenue growth for the company[7]. - The report indicates a substantial increase in overseas business, contributing to the overall revenue growth[7]. - The company is expanding its market presence in Europe, targeting a 20% increase in market share by the end of the fiscal year[21]. - The international business accounted for over 50% of total revenue, with overseas sales of liraglutide formulations and GLP-1 raw materials significantly contributing to growth, achieving a 189.79% increase in foreign revenue[76][78]. - The company plans to accelerate its global strategy in peptide and small nucleic acid formulations, as well as API and CDMO/CMO businesses, targeting markets in North America, South America, Europe, Asia, and the Middle East[38]. Research and Development - New product development includes a novel nasal spray for COVID-19, developed in collaboration with the Chinese Academy of Sciences[20]. - Clinical trials for the new GLP-1 receptor agonist are progressing, with Phase III trials expected to start in Q2 2024[20]. - The company aims to enhance its R&D efficiency and product competitiveness by integrating cutting-edge technologies such as biotechnology and artificial intelligence into its processes[38]. - The company is focused on expanding its research and development capabilities, particularly in peptide drug development, with over 15 years of experience in the field[159]. - The company is advancing multiple products towards market approval, including HY3000 and HY3001, which are in clinical trials aimed at obtaining Chinese market licenses[96]. Operational Efficiency and Cost Management - The company aims to reduce operational costs by 10% through improved supply chain management strategies[21]. - The company is investing 100 million RMB in new technology for drug manufacturing to improve efficiency and reduce costs[21]. - The management team has implemented refined operational processes across the supply chain, enhancing efficiency and service quality[58]. - The company has established a comprehensive quality management system, achieving certifications from multiple international regulatory bodies, including FDA and GMP[57]. Corporate Governance and Compliance - The company emphasizes strict quality control throughout the drug production process to mitigate risks related to product quality[129]. - The company has established a value management system to enhance transparency and align market value with intrinsic value[133]. - The company has established a transparent performance evaluation and incentive mechanism for directors, supervisors, and senior management, ensuring compliance with relevant laws and regulations[143]. - The company strictly adheres to legal requirements for information disclosure, ensuring timely and accurate communication with shareholders through designated media[144]. - The company maintains a clear separation of assets, personnel, finance, institutions, and business from its controlling shareholder, ensuring independent operations[148]. Shareholder Engagement and Social Responsibility - The company has committed to social responsibility initiatives, including poverty alleviation and ecological protection, while ensuring shareholder interests[146]. - The company ensures equal treatment of all shareholders, particularly minority shareholders, allowing them to fully exercise their rights[138]. - The company actively communicates with investors through various channels, enhancing understanding and recognition among stakeholders[145]. Future Outlook and Strategic Goals - Future development strategies and plans are outlined in the management discussion and analysis section, emphasizing the need for investors to recognize associated risks[7]. - The company anticipates 2025 to be a pivotal year for growth, driven by optimized product structure and improved operational efficiency[124]. - The company plans to enhance its international strategy by expanding overseas marketing, accelerating product registration, and strengthening global partnerships[122]. - The company is committed to addressing potential risks in drug innovation and development, ensuring a robust pipeline of products[126]. Internal Control and Risk Management - The company has established a strict internal control system to manage risks and ensure compliance, enhancing the internal audit function[190]. - The company has not reported any significant internal control deficiencies during the reporting period[191]. - The supervisory board found no significant risks during its oversight activities in the reporting period[179]. - Measures are in place to prevent core technology leakage, including confidentiality agreements and enhanced information security systems[128].